The Pentagon has put a new health policy into motion that could reshape how service members are screened for hormonal issues, with mandatory testosterone testing now required for men 30 and older. The move is tied to a bigger push for readiness, long-term health, and keeping troops strong enough for the demands of service.
Under the new guidance, active-duty and reserve men over 30 will get routine blood tests for testosterone deficiency. Younger men are not automatically swept in, but they can still be tested if they ask for it or if a clinician spots warning signs that suggest something is off.
Defense Secretary Pete Hegseth backed the effort earlier this year, saying the goal was to make sure troops have the right hormone levels to perform at their best. He framed it as more than a short-term fix, pointing to durability, resilience, and health that lasts well beyond a single deployment.
That message fits neatly with the Pentagon’s broader argument: health problems that go unnoticed can drag down readiness in ways that show up slowly, then all at once. Testosterone is not being treated as a buzzword here, but as one part of the body’s engine that can affect strength, recovery, and overall physical output.
For men, the rule follows a simple pattern. If testosterone levels come back low, the next step can be more evaluation, and in some cases voluntary hormone replacement therapy may be offered if a clinician thinks it makes sense.
The timing matters too, since testosterone naturally starts to decline as men move through their 30s and 40s. That drop does not automatically mean a medical problem, but it does make the screening policy more pointed for older troops who may already be feeling the effects.
Women are handled differently under the guidance. They will not be given routine testosterone blood tests, though they can be screened for fatigue and menstrual disruption, which may signal hormonal imbalance or energy-availability issues tied to physical stress.
The policy also spells out when off-label testosterone could be considered for women, especially postmenopausal women dealing with unusually low sexual desire. At the same time, the military is drawing a hard line against testosterone use for non-medical performance boosting without a doctor’s prescription.
That distinction matters because the military has always had to balance performance, fairness, and safety. In a setting where discipline rules everything, any treatment that could be seen as an edge has to be measured carefully, especially when the same substance can also have legitimate medical uses.
Still, the new guidelines are likely to stir debate among doctors who worry about casting too wide a net. Some endocrinologists have warned that universal testing could lead to unnecessary treatment or side effects, and they say the evidence is not solid enough to prove that mass screening will automatically improve readiness.
The Pentagon is betting that standardized testing and clearer treatment paths will catch real problems before they get worse. At the same time, the Food and Drug Administration is expected to hold its own meeting with experts later this month to talk about testosterone’s medical use, which suggests this issue is far from settled.
For now, the policy lands at the intersection of military fitness, medicine, and a broader cultural shift toward tracking hormone health more closely. In practical terms, it puts testosterone on the same kind of watch list that other readiness issues already live on, and it does so with a sharper focus on age, sex, and clinical judgment.
